SCRIP ASKS... What Does 2021 Hold For Biopharma?
A broad survey of the industry's expectations for the year to come.
Every December, Scrip asks industry leaders and experts to share their expectations for the year to come. With responses from more than 200 professionals, Scrip Asks… What Does 2021 Hold For Biopharma? provides an unprecedented insight into the biopharma universe's collective crystal ball. With the hopes of global humanity's recovery from the COVID-19 pandemic in 2021 resting so heavily on this sector, the series covers the following areas in consecutive installments:
- Tackling COVID-19
Biopharma leaders anticipate tackling COVID-19 will remain the top priority at least for the next few months. However, as Anne Heatherington, head of Takeda Pharmaceutical Co. Ltd.'s Data Sciences Institute, Research & Development, put it, the view is broadly that "in 2021, we'll see a way out of the pandemic led by pharma and biotech" and that this will lead to "increased visibility of the importance of what we all do for the health of society."
As Astrid Kurniawan, senior market access consultant, Informa Pharma Intelligence, pointed out, "COVID-19 has demonstrated that in times of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
